European Pharmacovigilance Risk Assessment Committee (PRAC) concludes that use of remdesivir is not associated with kidney problems

The European Medicines Agency’s PRAC has assessed all available information and concluded there is currently no evidence indicating that reported kidney problems are associated with the use of remdesivir. The risk of kidney injury will continue to be carefully monitored.

Source:

European Medicines Agency